# OnCo record bal0891 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bal0891/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bal0891" ;
  schema:name "BAL0891"@en ;
  schema:description "BAL0891 is an experimental medicine from SillaJen that blocks two enzymes cancer cells use to divide. It is in an early trial, and the FDA has given it orphan drug status for acute myeloid leukaemia."@en ;
  schema:url <https://onco.cc/drugs/bal0891/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.sillajen.com/eng/sub/pipeline_bal0891.html>, <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1162426>, <https://clinicaltrials.gov/study/NCT05768932> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "orphan-designation" ;
  onco:modality "Small-molecule kinase inhibitor" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:targets <https://onco.cc/targets/ttk/>, <https://onco.cc/targets/plk1/> ;
  onco:companies <https://onco.cc/companies/sillajen/> .